DUBLIN and LONDON - April 17, 2019-Medtronic plc (NYSE:MDT) today announced five-year outcomes from the VeClose Extension Study. Nick Morrison, M.D., Center for Vein Restoration, Mesa, Ariz., ...

The U.S. Food and Drug Administration (FDA) has recently cleared Medtronic plc's (MDT) VenaSeal closure system for use in the treatment of patients in the U.S., who suffer from venous reflux disease, ...

Medical device major Medtronic plc MDT recently unveiled 12-month results from its VeClose study, validating the clinical durability of its VenaSeal closure system, at the European Venous Forum 2015 ...

Medtronic announced today U.S. availability of its VenaSeal closure system. This is the first procedure of its kind approved for the treatment of symptomatic venous reflux (varicose veins) in the U.S.

12 month closure rates for the VenaSeal closure system comparable to radiofrequency ablation DUBLIN, Medtronic plc today announced the twelve-month results of the VeClose pivotal study, which ...

Please provide your email address to receive an email when new articles are posted on . The FDA today announced its approval of the VenaSeal closure system to permanently treat varicose veins of the ...

The U.S. Food and Drug Administration has approved Medtronic PLC’s VenaSeal system for the treatment of varicose veins. The system treats varicose veins by sealing them with an adhesive. The procedure ...

Healthy leg veins have valves that keep blood flowing to the heart. Venous reflux disease, also known as CVD, develops when the valves stop working properly and allow blood to flow backward (i.e., ...

Annually in India around 10 million people suffer with varicose veins, but not all consider varicose veins a serious medical condition and delay its treatment thus resulting into unbearable pain and ...